Li et al. proposed BIN3 as a potential prognostic biomarker in ESCA [22], while Lin et al. highlighted the important role of RSPO1 in regulating tumor immunity and suggested RSPO1 as a promising target for immunotherapy in ESCA [23], Deng et al. developed nomograms and risk classification models to predict the prognosis of patients with esophageal squamous cell carcinoma [24]. Here, RSPO1 is linked to esophageal squamous cell carcinoma.